NBIX - Neurocrine Biosciences Non-GAAP EPS of $1.20 misses by $0.09 revenue of $515.3M beats by $3.29M
2024-05-01 07:12:26 ET
More on Neurocrine Biosciences
- Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
- Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
- Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript
- Neurocrine Biosciences Q1 2024 Earnings Preview
- Neurocrine launches CAH community website ahead of FDA filing